Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Xing-Duo Dong"'
Autor:
Zeng-Hui Wei, Jagadish Koya, Nikita Acharekar, Jesus Trejos, Xing-Duo Dong, Francis A. Schanne, Charles R. Ashby, Sandra E. Reznik
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-16 (2023)
Abstract Alzheimer’s disease (AD) is a chronic degenerative brain disorder with no clear pathogenesis or effective cure, accounting for 60–80% of cases of dementia. In recent years, the importance of neuroinflammation in the pathogenesis of AD an
Externí odkaz:
https://doaj.org/article/893fcb60e9304622ad9b4df38e80801f
Autor:
Xing-Duo Dong, Meng Zhang, Chao-Yun Cai, Qiu-Xu Teng, Jing-Quan Wang, Yi-Ge Fu, Qingbin Cui, Ketankumar Patel, Dong-Tao Wang, Zhe-Sheng Chen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The KRAS-G12C inhibitor ARS-1620, is a novel specific covalent inhibitor of KRAS-G12C, possessing a strong targeting inhibitory effect on KRAS-G12C mutant tumors. Overexpression of ATP-binding cassette super-family B member 1 (ABCB1/P-gp) is one of t
Externí odkaz:
https://doaj.org/article/a06b350b27f64a4eb5eb02d4b307d432
Autor:
Xing-Duo Dong, Meng Zhang, Xiubin Ma, Jing-Quan Wang, Zi-Ning Lei, Qiu-Xu Teng, Yi-Dong Li, Lusheng Lin, Weiguo Feng, Zhe-Sheng Chen
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
Overexpression of ATP-binding cassette subfamily B member 1 (ABCB1) remains one of the most vital factors leading to multidrug resistance (MDR). It is important to enhance the effect and bioavailability of chemotherapeutic drugs that are substrates o
Externí odkaz:
https://doaj.org/article/10168d0f405f4d14a881562fed171ebb
Autor:
Meng Zhang, Xuan-Yu Chen, Xing-Duo Dong, Jing-Quan Wang, Weiguo Feng, Qiu-Xu Teng, Qingbin Cui, Jing Li, Xiang-Qi Li, Zhe-Sheng Chen
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Multidrug resistance (MDR) is a major challenge in the treatment of tumors. It refers to cancer cells become resistant to not only the therapeutic drug, but also cross-resistant to multiple drugs with distinct structures and mechanisms of action when
Externí odkaz:
https://doaj.org/article/8edc670bda9048f39fb50b9d6fd90c96
Autor:
Weiguo Feng, Meng Zhang, Zhuo-Xun Wu, Jing-Quan Wang, Xing-Duo Dong, Yuqi Yang, Qiu-Xu Teng, Xuan-Yu Chen, Qingbin Cui, Dong-Hua Yang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR. Erdafitinib is a tyrosine kinase inhibitor (TKI) of fibroblast growth factor rec
Externí odkaz:
https://doaj.org/article/811513a9c10b484dba7dff0cc71b3e7e
Autor:
Yi-Dong Li, Yong Mao, Xing-Duo Dong, Zi-Ning Lei, Yuqi Yang, Lizhu Lin, Charles R. Ashby, Dong-Hua Yang, Ying-Fang Fan, Zhe-Sheng Chen
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
In this study, we investigated the efficacy of methyl-cantharidimide (MCA), a cantharidin (CTD) analog, as an anticancer drug, in cancer cells overexpressing either ABCB1 or ABCG2 transporters and in cisplatin-resistant cancer cells. The results indi
Externí odkaz:
https://doaj.org/article/1a8e92859a3b498b91d255c49813f2ba
Autor:
Gao-Jie Ye, Chao-Yun Cai, Xing-Duo Dong, Zhuo-Xun Wu, Qiu-Xu Teng, Jing-Quan Wang, Zhe-Sheng Chen, Bo Wang
Publikováno v:
Bioorganic Chemistry. 135:106481
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4dc87274b3308ff72aab2b7ea6abd250
https://doi.org/10.1016/j.bioorg.2023.106481
https://doi.org/10.1016/j.bioorg.2023.106481
Publikováno v:
Cancer Research. 83:2843-2843
Overcoming ATP-binding cassette subfamily G member 2 (ABCG2)-mediated multidrug resistance (MDR) has attracted the attention of scientists because one of the critical factors leading to MDR is the overexpression of ABCG2. Identification of novel chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e3a500f08b39659e28b83fc6139912d
https://doi.org/10.1158/1538-7445.am2023-2843
https://doi.org/10.1158/1538-7445.am2023-2843
Publikováno v:
Drugs of today (Barcelona, Spain : 1998). 57(9)
The identification of oncogenic drivers and the subsequent development of targeted therapies have been established as biomarker-based care for metastatic non-small cell lung cancer (NSCLC) patients. Rearranged during transfection (RET) events have be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d3257f4038f18e274bc014ca6174aad
https://pubmed.ncbi.nlm.nih.gov/34586104
https://pubmed.ncbi.nlm.nih.gov/34586104
Autor:
Yi-Dong Li, Yong Mao, Xing-Duo Dong, Zi-Ning Lei, Yuqi Yang, Lizhu Lin, Dong-Hua Yang, Zhe-Sheng Chen
Publikováno v:
Cancer Research. 82:360-360
In this study, we investigated the underlying mechanism of action of methyl-cantharidimide (MCA), a cantharidin (CTD) analog, as an anticancer drug, in resistant cancer cells overexpressing either ABCB1 or ABCG2 and in cisplatin-resistant cancer cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::933e937d908d9ee9ab7ed541d38df455
https://doi.org/10.1158/1538-7445.am2022-360
https://doi.org/10.1158/1538-7445.am2022-360